Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruzzese

Showing results (741-750 of 766) with videos related to

Pageof 77
Sort By:
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Inflammatory Markers are Associated with Ischemic Stroke among Indigenous Africans: Evidence from the SIREN StudyMoustafa I Morsy, Fred S Sarfo, Osahon J Asowata, et al.
Current Research in Pharmacology and Drug Discovery|February 29, 2024
Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patientsSimone Parisi, Becciolini Andrea, Ditto Maria Chiara, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Medicina (Kaunas, Lithuania)|August 26, 2023
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort StudyMarino Paroli, Andrea Becciolini, Elena Bravi, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
ESC Heart Failure|February 5, 2025
Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF Registry)Stefania Paolillo, Christian Basile, Federica Marzano, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Minerva Medica|October 8, 2024
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritisAlberto Lo Gullo, Simone Parisi, Andrea Becciolini, et al.
Pageof 77

Showing results (741-750 of 766) with videos related to

Sort By:
Pageof 77
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Inflammatory Markers are Associated with Ischemic Stroke among Indigenous Africans: Evidence from the SIREN StudyMoustafa I Morsy, Fred S Sarfo, Osahon J Asowata, et al.
Current Research in Pharmacology and Drug Discovery|February 29, 2024
Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patientsSimone Parisi, Becciolini Andrea, Ditto Maria Chiara, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Medicina (Kaunas, Lithuania)|August 26, 2023
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort StudyMarino Paroli, Andrea Becciolini, Elena Bravi, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
ESC Heart Failure|February 5, 2025
Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF Registry)Stefania Paolillo, Christian Basile, Federica Marzano, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Minerva Medica|October 8, 2024
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritisAlberto Lo Gullo, Simone Parisi, Andrea Becciolini, et al.
Pageof 77